FDMT Retained Earnings vs Other Liab Analysis

FDMT Stock

USD 4.88 0.16 3.39%

4D Molecular financial indicator trend analysis is way more than just evaluating 4D Molecular Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether 4D Molecular Therapeutics is a good investment. Please check the relationship between 4D Molecular Retained Earnings and its Other Liab accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Retained Earnings vs Other Liab

Retained Earnings vs Other Liab Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of 4D Molecular Therapeutics Retained Earnings account and Other Liab. At this time, the significance of the direction appears to have almost identical trend.

The correlation between 4D Molecular's Retained Earnings and Other Liab is 0.95. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Other Liab in the same time period over historical financial statements of 4D Molecular Therapeutics, assuming nothing else is changed. The correlation between historical values of 4D Molecular's Retained Earnings and Other Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of 4D Molecular Therapeutics are associated (or correlated) with its Other Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Other Liab has no effect on the direction of Retained Earnings i.e., 4D Molecular's Retained Earnings and Other Liab go up and down completely randomly.

Correlation Coefficient

0.95

Relationship Direction	Positive
Relationship Strength	Very Strong

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Other Liab

Most indicators from 4D Molecular's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into 4D Molecular Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Sales General And Administrative To Revenue is likely to gain to 2.07 in 2025, whereas Selling General Administrative is likely to drop slightly above 21.7 M in 2025.

	2022	2023	2024	2025 (projected)
Interest Income	2.6M	9.2M	10.5M	11.1M
Net Interest Income	2.6M	9.2M	10.5M	11.1M

Interest Income Net Interest Income

4D Molecular fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.96	0.96	0.39	-0.91	0.95	0.85	-0.65	-0.96	-0.89	0.94	0.99	0.85	-0.39	0.88	1.0	0.32	0.98	0.9	-0.53	0.99	0.86	0.32	0.94	0.84	1.0
Other Current Liab	0.96		0.99	0.5	-0.88	0.86	0.82	-0.64	-0.88	-0.9	0.91	0.92	0.83	-0.26	0.93	0.95	0.36	0.93	0.97	-0.43	0.96	0.85	0.22	0.89	0.83	0.95
Total Current Liabilities	0.96	0.99		0.45	-0.9	0.87	0.83	-0.61	-0.9	-0.9	0.92	0.93	0.84	-0.24	0.95	0.95	0.44	0.94	0.96	-0.4	0.97	0.84	0.21	0.89	0.83	0.95
Total Stockholder Equity	0.39	0.5	0.45		-0.3	0.38	0.31	-0.33	-0.35	-0.48	0.19	0.35	0.37	0.33	0.33	0.4	0.35	0.36	0.46	-0.33	0.41	0.48	-0.38	0.5	0.38	0.41
Other Liab	-0.91	-0.88	-0.9	-0.3		-0.87	-0.95	0.8	0.87	0.95	-0.94	-0.88	-0.95	0.31	-0.91	-0.89	-0.27	-0.87	-0.87	0.37	-0.87	-0.94	-0.29	-0.89	-0.95	-0.89
Net Tangible Assets	0.95	0.86	0.87	0.38	-0.87		0.87	-0.67	-0.96	-0.87	0.88	0.96	0.87	-0.42	0.76	0.95	0.21	0.95	0.8	-0.69	0.95	0.87	0.31	0.99	0.85	0.95
Property Plant And Equipment Net	0.85	0.82	0.83	0.31	-0.95	0.87		-0.92	-0.79	-0.96	0.9	0.8	1.0	-0.27	0.84	0.82	0.04	0.84	0.86	-0.56	0.81	0.98	0.2	0.9	1.0	0.82
Current Deferred Revenue	-0.65	-0.64	-0.61	-0.33	0.8	-0.67	-0.92		0.54	0.87	-0.71	-0.57	-0.92	0.11	-0.68	-0.61	0.19	-0.64	-0.71	0.58	-0.59	-0.92	-0.02	-0.75	-0.93	-0.61
Net Debt	-0.96	-0.88	-0.9	-0.35	0.87	-0.96	-0.79	0.54		0.82	-0.89	-0.98	-0.79	0.45	-0.78	-0.97	-0.38	-0.94	-0.78	0.51	-0.96	-0.79	-0.39	-0.94	-0.77	-0.97
Retained Earnings	-0.89	-0.9	-0.9	-0.48	0.95	-0.87	-0.96	0.87	0.82		-0.87	-0.83	-0.96	0.12	-0.91	-0.86	-0.23	-0.88	-0.93	0.54	-0.87	-0.97	-0.05	-0.92	-0.97	-0.87
Accounts Payable	0.94	0.91	0.92	0.19	-0.94	0.88	0.9	-0.71	-0.89	-0.87		0.92	0.89	-0.53	0.87	0.93	0.14	0.91	0.88	-0.42	0.91	0.87	0.49	0.88	0.88	0.93
Cash	0.99	0.92	0.93	0.35	-0.88	0.96	0.8	-0.57	-0.98	-0.83	0.92		0.8	-0.44	0.83	1.0	0.35	0.97	0.84	-0.52	0.99	0.81	0.38	0.94	0.79	0.99
Non Current Assets Total	0.85	0.83	0.84	0.37	-0.95	0.87	1.0	-0.92	-0.79	-0.96	0.89	0.8		-0.27	0.83	0.83	0.04	0.83	0.86	-0.56	0.81	0.99	0.2	0.91	1.0	0.82
Non Currrent Assets Other	-0.39	-0.26	-0.24	0.33	0.31	-0.42	-0.27	0.11	0.45	0.12	-0.53	-0.44	-0.27		-0.08	-0.4	0.37	-0.32	-0.13	0.18	-0.34	-0.22	-0.97	-0.33	-0.22	-0.39
Other Assets	0.88	0.93	0.95	0.33	-0.91	0.76	0.84	-0.68	-0.78	-0.91	0.87	0.83	0.83	-0.08		0.86	0.46	0.87	0.95	-0.27	0.87	0.82	0.08	0.79	0.84	0.86
Cash And Short Term Investments	1.0	0.95	0.95	0.4	-0.89	0.95	0.82	-0.61	-0.97	-0.86	0.93	1.0	0.83	-0.4	0.86		0.34	0.98	0.88	-0.52	0.99	0.83	0.33	0.94	0.81	1.0
Net Receivables	0.32	0.36	0.44	0.35	-0.27	0.21	0.04	0.19	-0.38	-0.23	0.14	0.35	0.04	0.37	0.46	0.34		0.3	0.31	0.28	0.38	0.07	-0.27	0.21	0.05	0.35
Common Stock Total Equity	0.98	0.93	0.94	0.36	-0.87	0.95	0.84	-0.64	-0.94	-0.88	0.91	0.97	0.83	-0.32	0.87	0.98	0.3		0.9	-0.63	0.99	0.83	0.23	0.94	0.82	0.98
Common Stock Shares Outstanding	0.9	0.97	0.96	0.46	-0.87	0.8	0.86	-0.71	-0.78	-0.93	0.88	0.84	0.86	-0.13	0.95	0.88	0.31	0.9		-0.45	0.9	0.87	0.08	0.84	0.86	0.88
Non Current Liabilities Total	-0.53	-0.43	-0.4	-0.33	0.37	-0.69	-0.56	0.58	0.51	0.54	-0.42	-0.52	-0.56	0.18	-0.27	-0.52	0.28	-0.63	-0.45		-0.55	-0.58	0.04	-0.68	-0.56	-0.52
Other Current Assets	0.99	0.96	0.97	0.41	-0.87	0.95	0.81	-0.59	-0.96	-0.87	0.91	0.99	0.81	-0.34	0.87	0.99	0.38	0.99	0.9	-0.55		0.82	0.27	0.94	0.8	0.99
Other Stockholder Equity	0.86	0.85	0.84	0.48	-0.94	0.87	0.98	-0.92	-0.79	-0.97	0.87	0.81	0.99	-0.22	0.82	0.83	0.07	0.83	0.87	-0.58	0.82		0.14	0.93	0.99	0.83
Total Liab	0.32	0.22	0.21	-0.38	-0.29	0.31	0.2	-0.02	-0.39	-0.05	0.49	0.38	0.2	-0.97	0.08	0.33	-0.27	0.23	0.08	0.04	0.27	0.14		0.23	0.15	0.32
Net Invested Capital	0.94	0.89	0.89	0.5	-0.89	0.99	0.9	-0.75	-0.94	-0.92	0.88	0.94	0.91	-0.33	0.79	0.94	0.21	0.94	0.84	-0.68	0.94	0.93	0.23		0.9	0.94
Property Plant And Equipment Gross	0.84	0.83	0.83	0.38	-0.95	0.85	1.0	-0.93	-0.77	-0.97	0.88	0.79	1.0	-0.22	0.84	0.81	0.05	0.82	0.86	-0.56	0.8	0.99	0.15	0.9		0.81
Total Current Assets	1.0	0.95	0.95	0.41	-0.89	0.95	0.82	-0.61	-0.97	-0.87	0.93	0.99	0.82	-0.39	0.86	1.0	0.35	0.98	0.88	-0.52	0.99	0.83	0.32	0.94	0.81

Click cells to compare fundamentals

4D Molecular Account Relationship Matchups

4D Molecular fundamental ratios Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	288.3M	353.5M	261.8M	339.9M	390.9M	224.1M
Other Current Liab	8.4M	9.0M	6.7M	12.0M	13.8M	7.0M
Total Current Liabilities	16.7M	16.3M	15.7M	19.0M	21.8M	14.9M
Total Stockholder Equity	256.4M	(207.0M)	(314.5M)	307.8M	354.0M	371.7M
Other Liab	15.3M	15.2M	2.8M	1.3M	1.2M	1.1M
Net Tangible Assets	(73.0M)	256.4M	319.1M	231.3M	266.0M	279.3M
Property Plant And Equipment Net	5.1M	29.0M	35.3M	31.7M	36.4M	38.2M
Current Deferred Revenue	6.6M	2.6M	884K	273K	245.7K	233.4K
Net Debt	(276.7M)	(299.0M)	(202.5M)	(234.4M)	(211.0M)	(221.5M)
Retained Earnings	(135.7M)	(207.0M)	(314.5M)	(415.3M)	(373.8M)	(355.1M)
Accounts Payable	1.8M	4.8M	3.3M	3.5M	4.0M	2.6M
Cash	276.7M	315.4M	218.6M	249.1M	286.5M	192.5M
Non Current Assets Total	5.7M	38.1M	41.3M	43.3M	49.8M	52.3M
Non Currrent Assets Other	602K	(58.5M)	1.1M	684K	615.6K	646.4K
Other Assets	429K	677K	602K	1.1M	1.2M	640.8K
Cash And Short Term Investments	276.7M	315.4M	218.6M	288.2M	331.5M	198.7M
Net Receivables	978K	1.5M	47K	700K	630K	620.8K
Common Stock Shares Outstanding	26.7M	27.7M	32.4M	39.1M	45.0M	28.2M
Liabilities And Stockholders Equity	288.3M	353.5M	(284.0M)	339.9M	390.9M	410.4M
Non Current Liabilities Total	15.2M	18.0M	14.8M	13.1M	11.8M	11.2M
Other Current Assets	8.9M	8.5M	7.0M	8.4M	9.6M	5.7M
Other Stockholder Equity	103.7M	526.5M	547.0M	723.1M	831.6M	873.2M
Total Liab	31.9M	560.5M	30.5M	32.1M	36.9M	35.0M
Net Invested Capital	256.4M	319.1M	231.3M	307.8M	354.0M	371.7M
Property Plant And Equipment Gross	5.1M	34.3M	43.1M	43.6M	50.1M	52.6M
Total Current Assets	282.7M	315.4M	220.5M	296.6M	341.1M	202.1M
Accumulated Other Comprehensive Income	(288.3M)	(423K)	(1.2M)	16K	18.4K	19.3K
Non Current Liabilities Other	1.9M	17.8M	14.6M	248K	285.2K	270.9K
Net Working Capital	265.9M	239.9M	204.8M	277.6M	319.3M	178.0M
Property Plant Equipment	5.0M	5.1M	29.0M	22.3M	25.6M	26.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC